Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Organic / Comparable Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q4 2025
1.1%
Period ended Dec 31, 2025
Change on a year earlier
+11.3 pts
-10.2% in Q4 2024
History
40 quarters
Since Q4 2015
Sources
40
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Organic / Comparable Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | 1.1% | +11.3 pts | SEC Filing (0001628280-26-002982) ↗ |
| Q3 2025 | Sep 30, 2025 | 0.8% | +2.9 pts | SEC Filing (0001628280-25-045049) ↗ |
| Q2 2025 | Jun 30, 2025 | -3.4% | +6.0 pts | SEC Filing (0001628280-25-035135) ↗ |
| Q1 2025 | Mar 31, 2025 | -3.5% | +8.2 pts | SEC Filing (0001628280-25-017924) ↗ |
| Q4 2024 | Dec 31, 2024 | -10.2% | +4.7 pts | SEC Filing (0001628280-25-002092) ↗ |
| Q3 2024 | Sep 30, 2024 | -2.1% | +25.4 pts | SEC Filing (0001628280-24-042893) ↗ |
| Q2 2024 | Jun 30, 2024 | -9.4% | +22.7 pts | SEC Filing (0001628280-24-032182) ↗ |
| Q1 2024 | Mar 31, 2024 | -11.7% | – | SEC Filing (0001628280-24-016497) ↗ |
| Q4 2023 | Dec 31, 2023 | -14.9% | +29.8 pts | SEC Filing (0001628280-24-002009) ↗ |
| Q3 2023 | Sep 30, 2023 | -27.5% | +16.8 pts | SEC Filing (0001628280-23-034544) ↗ |
| Q2 2023 | Jun 30, 2023 | -32.1% | -7.9 pts | SEC Filing (0001628280-23-025156) ↗ |
| Q4 2022 | Dec 31, 2022 | -44.7% | -16.3 pts | SEC Filing (0001628280-23-001516) ↗ |
| Q3 2022 | Sep 30, 2022 | -44.3% | -18.7 pts | SEC Filing (0001628280-22-026588) ↗ |
| Q2 2022 | Jun 30, 2022 | -24.2% | -1.1 pts | SEC Filing (0001104659-22-081006) ↗ |
| Q1 2022 | Mar 31, 2022 | -3.0% | -215.0 pts | SEC Filing (0001104659-22-047560) ↗ |
| Q4 2021 | Dec 31, 2021 | -28.4% | -336.7 pts | SEC Filing (0001104659-22-007648) ↗ |
| Q3 2021 | Sep 30, 2021 | -25.6% | -339.2 pts | SEC Filing (0001104659-21-127874) ↗ |
| Q2 2021 | Jun 30, 2021 | -23.1% | -264.5 pts | SEC Filing (0001104659-21-094680) ↗ |
| Q1 2021 | Mar 31, 2021 | 212.0% | +181.7 pts | SEC Filing (0001104659-21-052205) ↗ |
| Q4 2020 | Dec 31, 2020 | 308.3% | +312.7 pts | SEC Filing (0001104659-21-007942) ↗ |
| Q3 2020 | Sep 30, 2020 | 313.6% | +320.0 pts | SEC Filing (0001104659-20-116611) ↗ |
| Q2 2020 | Jun 30, 2020 | 241.4% | +250.7 pts | SEC Filing (0001104659-20-083929) ↗ |
| Q1 2020 | Mar 31, 2020 | 30.3% | +35.4 pts | SEC Filing (0001104659-20-047187) ↗ |
| Q4 2019 | Dec 31, 2019 | -4.4% | -8.2 pts | SEC Filing (0001104659-20-005717) ↗ |
| Q3 2019 | Sep 30, 2019 | -6.4% | -12.5 pts | SEC Filing (0001104659-19-054283) ↗ |
| Q2 2019 | Jun 30, 2019 | -9.3% | -15.3 pts | SEC Filing (0001104659-19-040664) ↗ |
| Q1 2019 | Mar 31, 2019 | -5.1% | -6.4 pts | SEC Filing (0001104659-19-021809) ↗ |
| Q4 2018 | Dec 31, 2018 | 3.8% | +1.4 pts | SEC Filing (0001104659-19-002848) ↗ |
| Q3 2018 | Sep 30, 2018 | 6.1% | +5.0 pts | SEC Filing (0001104659-18-062380) ↗ |
| Q2 2018 | Jun 30, 2018 | 6.0% | +10.1 pts | SEC Filing (0001104659-18-045642) ↗ |
| Q1 2018 | Mar 31, 2018 | 1.3% | -2.6 pts | SEC Filing (0001104659-18-024701) ↗ |
| Q4 2017 | Dec 31, 2017 | 2.4% | +9.3 pts | SEC Filing (0001104659-18-003691) ↗ |
| Q3 2017 | Sep 30, 2017 | 1.1% | +1.4 pts | SEC Filing (0001104659-17-062667) ↗ |
| Q2 2017 | Jun 30, 2017 | -4.1% | -7.9 pts | SEC Filing (0001104659-17-045904) ↗ |
| Q1 2017 | Mar 31, 2017 | 3.9% | +6.7 pts | SEC Filing (0001104659-17-024344) ↗ |
| Q4 2016 | Dec 31, 2016 | -6.9% | -3.0 pts | SEC Filing (0001104659-17-003920) ↗ |
| Q3 2016 | Sep 30, 2016 | -0.3% | – | SEC Filing (0001104659-16-150813) ↗ |
| Q2 2016 | Jun 30, 2016 | 3.8% | – | SEC Filing (0001104659-16-133433) ↗ |
| Q1 2016 | Mar 31, 2016 | -2.8% | – | SEC Filing (0001104659-16-112689) ↗ |
| Q4 2015 | Dec 31, 2015 | -3.9% | – | SEC Filing (0001104659-16-091861) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Organic / Comparable Sales Growth (%) (%), quarterly Q4 2015–Q4 2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-mol-leg-yoy-org
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.